Profil
Tina Abild Olesen is currently Vice Chairman at World Diabetes Foundation, Managing Director at Novo Nordisk Pharma GmbH, and Director at Embla Medical hf since 2024.
Formerly, Ms. Olesen was Senior Vice President-Global Diabetes Franchise at Novo Nordisk A from 2022 to 2025.
Education includes graduate and MBA degrees from Copenhagen Business School.
Aktiva positioner av Tina Olesen
| Företag | Position | Start |
|---|---|---|
| EMBLA MEDICAL HF. | Direktör/Styrelseledamot | 2024-03-01 |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Verkställande Direktör | - |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Direktör/Styrelseledamot | - |
Tidigare kända positioner av Tina Olesen
| Företag | Position | Slut |
|---|---|---|
| NOVO NORDISK A/S | Företagsledare/Principal | 2025-08-01 |
Tina Olesens utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Embla Medical hf
Embla Medical hf Medical SpecialtiesHealth Technology Provides non-invasive orthopedic products and support services | Health Technology |
Copenhagen Business School
Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
















